



## Clinical trial results:

**An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously participated in the PROUD-PV Study**

### Summary

EudraCT number	2014-001357-17
Trial protocol	HU AT CZ PL SK BG ES DE
Global end of trial date	29 April 2021

### Results information

Result version number	v1 (current)
This version publication date	30 March 2022
First version publication date	30 March 2022

### Trial information

#### Trial identification

Sponsor protocol code	CONTINUATION-PV
-----------------------	-----------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	AOP Orphan Pharmaceuticals AG
Sponsor organisation address	Leopold-Ungar-Platz 2, Wien, Austria, 1190
Public contact	Clinical Project Manager, AOP Orphan Pharmaceuticals AG, +43 1503724446, continuation-pv@aoporphan.com
Scientific contact	Clinical Project Manager, AOP Orphan Pharmaceuticals AG, +43 1503724446, continuation-pv@aoporphan.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	19 July 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	29 April 2021
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

- To assess the long-term efficacy of AOP2014 or BAT in terms of disease response rate in patients diagnosed with PV, who were previously treated with AOP2014 or HU in the PROUD-PV study and who completed this Study.
- To assess the long-term efficacy including changes in disease burden present during PROUD-PV study in patients diagnosed with PV, who were previously treated with AOP2014 or HU in the PROUD-PV study. Disease burden is defined as disease-related signs (clinically significant splenomegaly) and disease-related symptoms (microvascular disturbances, pruritus, headache), assessed by investigator.

Protection of trial subjects:

The Investigator obtained a freely given signed ICF, with name and date and time noted by the patient before the patient was exposed to any study-related procedure. The study was carried out in compliance with the principles of Good Clinical Practice (GCP), data protection and confidentiality were handled in compliance with local laws.

Background therapy:

Low dose aspirin (acetylsalicylic acid) (100 mg/day) is to be given to all patients for the duration of study treatment, unless contraindicated.

Evidence for comparator:

The PROUD-PV Study compared the investigational medicinal product (IMP) AOP2014 to HU, an established first-line treatment option currently approved in several European countries for PV patients requiring a cytoreductive therapy (Barbui et al, 2011). This study (CONTINUATION-PV) is a follow-on study designed to provide long-term evaluation of AOP2014 in patients with PV (who received the AOP2014 during the PROUD-PV Study) and of BAT in patients with PV (who received HU during the PROUD-PV Study). The integration of the patients who participated in the PEN-PV Study will contribute to this long-term evaluation of the IMP as well as to an alternative mode of administration (pre-filled injection pen).

Actual start date of recruitment	25 November 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Italy: 1
Country: Number of subjects enrolled	Poland: 27
Country: Number of subjects enrolled	Romania: 9
Country: Number of subjects enrolled	Slovakia: 10
Country: Number of subjects enrolled	Spain: 1
Country: Number of subjects enrolled	Austria: 19
Country: Number of subjects enrolled	Bulgaria: 45

Country: Number of subjects enrolled	Czechia: 26
Country: Number of subjects enrolled	France: 13
Country: Number of subjects enrolled	Germany: 6
Country: Number of subjects enrolled	Hungary: 34
Country: Number of subjects enrolled	Russian Federation: 33
Country: Number of subjects enrolled	Ukraine: 30
Worldwide total number of subjects	254
EEA total number of subjects	191

Notes:

---

### **Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	174
From 65 to 84 years	79
85 years and over	1

## Subject disposition

### Recruitment

Recruitment details:

Patients who completed the PROUD-PV Study and fulfilled inclusion criteria were asked to participate in this study.

### Pre-assignment

Screening details:

Patients who completed the PROUD-PV Study and fulfill inclusion and exclusion criteria were enrolled into the study after giving their informed consent. Out of 217 patients who completed the PROUD-PV, 171 patients were enrolled. Because of a serious breach, 2 patients were later excluded from the analyses, 169 patients were included.

### Period 1

Period 1 title	Overall treatment period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	AOP2014

Arm description:

Patients treated with AOP2014. The dose of AOP2014 was adjusted to the dose which delivered the optimal disease response.

Arm type	Experimental
Investigational medicinal product name	AOP2014
Investigational medicinal product code	ropeginterferon alfa-2b
Other name	Peg-P-IFN- $\alpha$ -2b
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

AOP2014 was administered at the starting dose of 100  $\mu$ g every 2 weeks for up to 12 months of treatment. During the initial treatment phase (first 12 weeks following randomization), the dose of AOP2014 was adjusted to the dose which delivered the optimal disease response (Hematocrit [Hct] <45%, platelets <400 x 10<sup>9</sup>/L and leukocytes <10 x 10<sup>9</sup>/L). If no complete response was achieved, patients were treated at the individual highest tolerable dose, which had been achieved and kept during the maintenance treatment phase.

<b>Arm title</b>	Control
------------------	---------

Arm description:

Patients treated with Hydroxyurea or Best Available Treatment

Arm type	Active comparator
Investigational medicinal product name	Hydroxyurea
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Hydroxyurea was administered per os at the starting dose of 500 mg daily for up to 12 months of treatment. During the initial treatment phase (first 12 weeks following randomization), the dose of Hydroxyurea was adjusted to the dose which delivered the optimal disease response (Hematocrit [Hct] <45%, platelets <400 x 10<sup>9</sup>/L and leukocytes <10 x 10<sup>9</sup>/L). If no complete response was achieved, patients were treated at the individual highest tolerable dose, which had been achieved and kept during the maintenance treatment phase.

<b>Number of subjects in period 1</b>	AOP2014	Control
Started	127	127
EOT in PROUD-PV	106	111
Enrollment to CONTINUATION-PV	95	76
Analysed in CONTINUATION-PV	95	74
Completed	67	52
Not completed	60	75
Consent withdrawn by subject	4	6
Adverse event, continuation not possible	7	2
Completed PROUD-PV but not enrolled in CONTI	11	35
Other	6	12
Lost to follow-up	2	2
Following adverse events	4	-
Serious breach at site	-	2
Discontinued in PROUD-PV	21	16
Administrative reason	2	-
Lack of efficacy	3	-

## Baseline characteristics

### Reporting groups

Reporting group title	AOP2014
Reporting group description: Patients treated with AOP2014. The dose of AOP2014 was adjusted to the dose which delivered the optimal disease response.	
Reporting group title	Control
Reporting group description: Patients treated with Hydroxyurea or Best Available Treatment	

Reporting group values	AOP2014	Control	Total
Number of subjects	127	127	254
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	90	84	174
From 65-84 years	36	43	79
85 years and over	1	0	1
Age continuous			
Units: years			
median	60.0	60.0	-
inter-quartile range (Q1-Q3)	52.0 to 66.0	48.0 to 67.0	-
Gender categorical			
Units: Subjects			
Female	68	67	135
Male	59	60	119
Race			
Units: Subjects			
White	127	127	254
Durration of Polycythemia Vera			
Units: month			
arithmetic mean	12.6	15.7	-
standard deviation	± 24.70	± 25.65	-

### Subject analysis sets

Subject analysis set title	PROUD+CONTI AOP2014
Subject analysis set type	Safety analysis
Subject analysis set description: All the AOP2014 patients treated in PROUD-PV study, regardless whether they continued to CONTINUATION-PV	
Subject analysis set title	PROUD+CONTI Control

Subject analysis set type	Safety analysis
Subject analysis set description: All the control patients treated in PROUD-PV study, regardless whether they continued to CONTINUATION-PV	
Subject analysis set title	CONTI FAS AOP2014
Subject analysis set type	Full analysis
Subject analysis set description: All AOP2014 patients enrolled to CONTINUATION-PV (without the subjects from the site with serious breach)	
Subject analysis set title	CONTI FAS Control
Subject analysis set type	Full analysis
Subject analysis set description: All AOP2014 patients enrolled to CONTINUATION-PV (without the subjects from the site with serious breach)	
Subject analysis set title	CONTI PPS AOP2014
Subject analysis set type	Per protocol
Subject analysis set description: Subject from the CONTI FAS AOP2014 set who have no protocol deviation which would lead to exclusion from PPS at all assessment visits.	
Subject analysis set title	CONTI PPS Control
Subject analysis set type	Per protocol
Subject analysis set description: Subject from the CONTI FAS AOP2014 set who have no protocol deviation which would lead to exclusion from PPS at all assessment visits.	

<b>Reporting group values</b>	PROUD+CONTI AOP2014	PROUD+CONTI Control	CONTI FAS AOP2014
Number of subjects	127	127	95
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	90	84	75
From 65-84 years	36	43	19
85 years and over	1	0	1
Age continuous Units: years			
median	60	60	58
inter-quartile range (Q1-Q3)	52 to 66	48 to 67	50 to 64
Gender categorical Units: Subjects			
Female	68	67	48
Male	59	60	47
Race Units: Subjects			
White	127	127	95

Durration of Polycythemia Vera Units: month arithmetic mean standard deviation	12.6 ± 24.70	15.7 ± 25.65	12.1 ± 25.82
---	-----------------	-----------------	-----------------

<b>Reporting group values</b>	CONTI FAS Control	CONTI PPS AOP2014	CONTI PPS Control
Number of subjects	74	92	72
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	49	72	48
From 65-84 years	25	19	24
85 years and over	0	1	0
Age continuous Units: years median inter-quartile range (Q1-Q3)	60 50 to 66	58.5 50.5 to 64	60 50 to 65.5
Gender categorical Units: Subjects			
Female	39	47	38
Male	35	45	34
Race Units: Subjects			
White	74	92	72
Durration of Polycythemia Vera Units: month arithmetic mean standard deviation	10.1 ± 17.54	12.2 ± 26.18	10.4 ± 17.71

## End points

### End points reporting groups

Reporting group title	AOP2014
-----------------------	---------

Reporting group description:

Patients treated with AOP2014. The dose of AOP2014 was adjusted to the dose which delivered the optimal disease response.

Reporting group title	Control
-----------------------	---------

Reporting group description:

Patients treated with Hydroxyurea or Best Available Treatment

Subject analysis set title	PROUD+CONTI AOP2014
----------------------------	---------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

All the AOP2014 patients treated in PROUD-PV study, regardless whether they continued to CONTINUATION-PV

Subject analysis set title	PROUD+CONTI Control
----------------------------	---------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

All the control patients treated in PROUD-PV study, regardless whether they continued to CONTINUATION-PV

Subject analysis set title	CONTI FAS AOP2014
----------------------------	-------------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

All AOP2014 patients enrolled to CONTINUATION-PV (without the subjects from the site with serious breach)

Subject analysis set title	CONTI FAS Control
----------------------------	-------------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

All AOP2014 patients enrolled to CONTINUATION-PV (without the subjects from the site with serious breach)

Subject analysis set title	CONTI PPS AOP2014
----------------------------	-------------------

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:

Subject from the CONTI FAS AOP2014 set who have no protocol deviation which would lead to exclusion from PPS at all assessment visits.

Subject analysis set title	CONTI PPS Control
----------------------------	-------------------

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:

Subject from the CONTI FAS AOP2014 set who have no protocol deviation which would lead to exclusion from PPS at all assessment visits.

### Primary: Complete haematologic response with spleen size criterion

End point title	Complete haematologic response with spleen size criterion
-----------------	---

End point description:

Disease response defined as haematologic response: Hct<45% without phlebotomy (at least 3 months since the last phlebotomy), PLTs<400 x 10<sup>9</sup>/L, WBCs<10 x 10<sup>9</sup>/L, and normal spleen size  
The discontinued patients are assumed to be Non-responders

End point type	Primary
----------------	---------

End point timeframe:

Each assesment visit (each 3 months)

<b>End point values</b>	AOP2014	Control	CONTI FAS AOP2014	CONTI FAS Control
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	95	74	95	74
Units: count and percentage of subject				
Responder at Month 72	32	15	32	15
Non-responder at Month 72, including discontinued	54	45	54	45
Discontinued at Month 72	25	20	25	20

<b>End point values</b>	CONTI PPS AOP2014	CONTI PPS Control		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	92	72		
Units: count and percentage of subject				
Responder at Month 72	30	15		
Non-responder at Month 72, including discontinued	48	45		
Discontinued at Month 72	22	20		

<b>Attachments (see zip file)</b>	Analyses in per-protocol set/Primary 1 PPS.xlsx Analysis in Full-analyses set/Primary 1 FAS.xlsx
-----------------------------------	---

## Statistical analyses

<b>Statistical analysis title</b>	Longitudinal analysis over 0 - 72 months FAS
Statistical analysis description:	
Longitudinal analysis to evaluate trends over treatment period of 72 months.	
Comparison groups	CONTI FAS AOP2014 v CONTI FAS Control
Number of subjects included in analysis	169
Analysis specification	Pre-specified
Analysis type	other <sup>[1]</sup>
P-value	= 0.1289 <sup>[2]</sup>
Method	Mixed models analysis
Parameter estimate	Risk ratio (RR)
Point estimate	1.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.89
upper limit	2.46
Variability estimate	Standard error of the mean

Notes:

[1] - Study the trend in responses in the treatment period

[2] - The goal was to study the trend through the years. The p-value in late months is higher because of high number of discontinued patients (= Non-responders). Check the attachment for more information.

<b>Statistical analysis title</b>	Longitudinal analysis over 0 - 72 months PPS
-----------------------------------	--

Statistical analysis description:

Longitudinal analysis to evaluate trends over treatment period of 72 months.

Comparison groups	CONTI PPS AOP2014 v CONTI PPS Control
Number of subjects included in analysis	164
Analysis specification	Pre-specified
Analysis type	other <sup>[3]</sup>
P-value	= 0.0987 <sup>[4]</sup>
Method	Mixed models analysis
Parameter estimate	Risk ratio (RR)
Point estimate	1.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.92
upper limit	2.55
Variability estimate	Standard error of the mean

Notes:

[3] - Study the trend in responses in the treatment period

[4] - The goal was to study the trend through the years. The p-value in late months is higher because of high number of discontinued patients (= Non-responders). Check the attachment for more information.

### **Primary: Complete haematologic response and improvement of disease burden**

End point title	Complete haematologic response and improvement of disease burden
-----------------	--

End point description:

Disease response defined as haematologic response (Hct<45% without phlebotomy (at least 3 months since the last phlebotomy), PLTs<400 x 10<sup>9</sup>/L, WBCs<10 x 10<sup>9</sup>/L), resolution and/or clinically improvement of disease-related signs (clinically significant splenomegaly) and disease-related symptoms (microvascular disturbances, pruritus, headache).

End point type	Primary
----------------	---------

End point timeframe:

Each assesment visit (each 3 months)

<b>End point values</b>	AOP2014	Control	CONTI FAS AOP2014	CONTI FAS Control
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	95	74	95	74
Units: count and percentage of subject				
Responder at Month 72	35	17	35	17
Non-responder at Month 72, including discontinued	53	49	53	49
Discontinued at Month 72	25	20	25	20

<b>End point values</b>	CONTI PPS AOP2014	CONTI PPS Control		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	92	72		
Units: count and percentage of subject				
Responder at Month 72	35	15		
Non-responder at Month 72, including discontinued	43	45		
Discontinued at Month 72	22	20		

<b>Attachments (see zip file)</b>	Analysis in Full-analyses set/Primary 2 FAS.xlsx Analysis in Per-protocol set/Primary 2 PPS.xlsx
-----------------------------------	---

### Statistical analyses

<b>Statistical analysis title</b>	Longitudinal analysis over 0 - 72 months FAS
-----------------------------------	--

Statistical analysis description:

Longitudinal analysis to evaluate trends over treatment period of 72 months.

Comparison groups	CONTI FAS Control v CONTI FAS AOP2014
Number of subjects included in analysis	169
Analysis specification	Pre-specified
Analysis type	other <sup>[5]</sup>
P-value	= 0.0584 <sup>[6]</sup>
Method	Mixed models analysis
Parameter estimate	Risk ratio (RR)
Point estimate	1.58
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.98
upper limit	2.52
Variability estimate	Standard error of the mean

Notes:

[5] - Study the trend in responses in the treatment period

[6] - The goal was to study the trend through the years. The p-value in late months is higher because of high number of discontinued patients (= Non-responders). Check the attachment for more information.

<b>Statistical analysis title</b>	Longitudinal analysis over 0 - 72 months PPS
-----------------------------------	--

Statistical analysis description:

Longitudinal analysis to evaluate trends over treatment period of 72 months.

Comparison groups	CONTI PPS AOP2014 v CONTI PPS Control
Number of subjects included in analysis	164
Analysis specification	Pre-specified
Analysis type	other <sup>[7]</sup>
P-value	= 0.0167 <sup>[8]</sup>
Method	Mixed models analysis
Parameter estimate	Risk ratio (RR)
Point estimate	1.82

Confidence interval	
level	95 %
sides	2-sided
lower limit	1.11
upper limit	2.97
Variability estimate	Standard error of the mean

Notes:

[7] - Study the trend in responses in the treatment period

[8] - The goal was to study the trend through the years. The p-value in late months is higher because of high number of discontinued patients (= Non-responders). Check the attachment for more information.

### Secondary: Complete haematologic response (without spleen size criterion)

End point title	Complete haematologic response (without spleen size criterion)
-----------------	--

End point description:

Disease response defined as haematologic response: Hct<45% without phlebotomy (at least 3 months since the last phlebotomy), PLTs<400 x 10<sup>9</sup>/L, WBCs<10 x 10<sup>9</sup>/L. The discontinued patients are assumed to be Non-responders

End point type	Secondary
----------------	-----------

End point timeframe:

Each assesment visit (each 3 months)

End point values	AOP2014	Control	CONTI FAS AOP2014	CONTI FAS Control
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	95	74	95	74
Units: count and percentage of subject				
Responder at Month 72	48	22	48	22
Non-responder at Month 72, including discontinued	40	41	40	41
Discontinued at Month 72	25	20	25	20

End point values	CONTI PPS AOP2014	CONTI PPS Control		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	92	72		
Units: count and percentage of subject				
Responder at Month 72	45	19		
Non-responder at Month 72, including discontinued	33	41		
Discontinued at Month 72	22	20		

<b>Attachments (see zip file)</b>	Analysis in Full-analyses set/Secondary 1 FAS.xlsx Analysis in Per-protocol set/Secondary 1 PPS.xlsx
-----------------------------------	---

## Statistical analyses

<b>Statistical analysis title</b>	Longitudinal analysis over 0 - 72 months FAS
-----------------------------------	--

Statistical analysis description:

Longitudinal analysis to evaluate trends over treatment period of 72 months.

Comparison groups	CONTI FAS AOP2014 v CONTI FAS Control
Number of subjects included in analysis	169
Analysis specification	Pre-specified
Analysis type	other <sup>[9]</sup>
P-value	= 0.0216 <sup>[10]</sup>
Method	Mixed models analysis
Parameter estimate	Risk ratio (RR)
Point estimate	1.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.07
upper limit	2.26
Variability estimate	Standard error of the mean

Notes:

[9] - Study the trend in responses in the treatment period

[10] - The goal was to study the trend through the years. The p-value in late months is higher because of high number of discontinued patients (= Non-responders). Check the attachment for more information.

<b>Statistical analysis title</b>	Longitudinal analysis over 0 - 72 months PPS
-----------------------------------	--

Statistical analysis description:

Longitudinal analysis to evaluate trends over treatment period of 72 months. in per-protocol set.

Comparison groups	CONTI PPS AOP2014 v CONTI PPS Control
Number of subjects included in analysis	164
Analysis specification	Pre-specified
Analysis type	other <sup>[11]</sup>
P-value	= 0.0034 <sup>[12]</sup>
Method	Mixed models analysis
Parameter estimate	Risk ratio (RR)
Point estimate	1.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.22
upper limit	2.74
Variability estimate	Standard error of the mean

Notes:

[11] - Study the trend in responses in the treatment period

[12] - The goal was to study the trend through the years. The p-value in late months is higher because of high number of discontinued patients (= Non-responders). Check the attachment for more information.

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Timeframe for AE

Adverse event reporting additional description:

AE additional description

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.0
--------------------	------

### Reporting groups

Reporting group title	AOP2014
-----------------------	---------

Reporting group description: -

Reporting group title	Control
-----------------------	---------

Reporting group description: -

<b>Serious adverse events</b>	AOP2014	Control	
Total subjects affected by serious adverse events			
subjects affected / exposed	32 / 127 (25.20%)	35 / 127 (27.56%)	
number of deaths (all causes)	3	5	
number of deaths resulting from adverse events	3	5	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute leukaemia	Additional description: Acute leukaemia		
subjects affected / exposed	0 / 127 (0.00%)	2 / 127 (1.57%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	1 / 1	
Adrenal adenoma	Additional description: Adrenal adenoma		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma	Additional description: Basal cell carcinoma		
subjects affected / exposed	0 / 127 (0.00%)	2 / 127 (1.57%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct cancer	Additional description: Bile duct cancer		

subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain neoplasm malignant	Additional description: Brain neoplasm malignant		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer	Additional description: Colon cancer		
subjects affected / exposed	1 / 127 (0.79%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioblastoma	Additional description: Glioblastoma		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Malignant melanoma	Additional description: Malignant melanoma		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelofibrosis	Additional description: Myelofibrosis		
subjects affected / exposed	1 / 127 (0.79%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm of appendix	Additional description: Neoplasm of appendix		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal adenocarcinoma	Additional description: Rectal adenocarcinoma		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal oncocyoma	Additional description: Renal oncocyoma		

subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spermatocytic seminoma			
Additional description: Spermatocytic seminoma			
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid adenoma			
Additional description: Thyroid adenoma			
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Embolism			
Additional description: Embolism			
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
Additional description: Hypertension			
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
Additional description: Peripheral arterial occlusive disease			
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis superficial			
Additional description: Thrombophlebitis superficial			
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Aortic valve replacement			
Additional description: Aortic valve replacement			
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid endarterectomy			
Additional description: Carotid endarterectomy			

subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystectomy			
Additional description: Cholecystectomy			
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colectomy			
Additional description: Colectomy			
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart valve operation			
Additional description: Heart valve operation			
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip arthroplasty			
Additional description: Hip arthroplasty			
subjects affected / exposed	0 / 127 (0.00%)	2 / 127 (1.57%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Knee arthroplasty			
Additional description: Knee arthroplasty			
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Knee operation			
Additional description: Knee operation			
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rehabilitation therapy			
Additional description: Rehabilitation therapy			
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst excision			
Additional description: Renal cyst excision			

subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shoulder arthroplasty	Additional description: Shoulder arthroplasty		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Multi-organ failure	Additional description: Multi-organ failure		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death	Additional description: Death		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Oedema peripheral	Additional description: Oedema peripheral		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia	Additional description: Pyrexia		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden death	Additional description: Sudden death		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Reproductive system and breast disorders			
Uterine polyp	Additional description: Uterine polyp		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Psychiatric disorders			
Depression	Additional description: Depression		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Angiocardiogram	Additional description: Angiocardiogram		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coagulation time prolonged	Additional description: Coagulation time prolonged		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Fall	Additional description: Fall		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis radiation	Additional description: Gastroenteritis radiation		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage	Additional description: Post procedural haemorrhage		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident	Additional description: Road traffic accident		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Skin laceration	Additional description: Skin laceration		

subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Skull fractured base</b>	Additional description: Skull fractured base		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Subcutaneous haematoma</b>	Additional description: Subcutaneous haematoma		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Upper limb fracture</b>	Additional description: Upper limb fracture		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Uterine dehiscence</b>	Additional description: Uterine dehiscence		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Congenital, familial and genetic disorders</b>			
<b>Porphyria non-acute</b>	Additional description: Porphyria non-acute		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cardiac disorders</b>			
<b>Angina unstable</b>	Additional description: Angina unstable		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Atrial fibrillation</b>	Additional description: Atrial fibrillation		
subjects affected / exposed	3 / 127 (2.36%)	2 / 127 (1.57%)	
occurrences causally related to treatment / all	1 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	

Atrial flutter subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Atrial flutter		
	1 / 127 (0.79%)	0 / 127 (0.00%)	
	0 / 1	0 / 0	
Cardiac failure subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Cardiac failure		
	0 / 127 (0.00%)	3 / 127 (2.36%)	
	0 / 0	0 / 3	
Cardiac failure acute subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Cardiac failure acute		
	0 / 127 (0.00%)	1 / 127 (0.79%)	
	0 / 0	0 / 2	
Cardiac failure chronic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Cardiac failure chronic		
	1 / 127 (0.79%)	0 / 127 (0.00%)	
	0 / 1	0 / 0	
Pericardial effusion subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Pericardial effusion		
	0 / 127 (0.00%)	1 / 127 (0.79%)	
	0 / 0	0 / 1	
Left ventricular failure subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Left ventricular failure		
	0 / 127 (0.00%)	1 / 127 (0.79%)	
	0 / 0	0 / 1	
Supraventricular tachycardia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Supraventricular tachycardia		
	1 / 127 (0.79%)	0 / 127 (0.00%)	
	0 / 1	0 / 0	
Sinus tachycardia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Sinus tachycardia		
	1 / 127 (0.79%)	0 / 127 (0.00%)	
	0 / 1	0 / 0	
Nervous system disorders			

Cerebrovascular accident subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Cerebrovascular accident		
	0 / 127 (0.00%)	1 / 127 (0.79%)	
	0 / 0	0 / 1	
	0 / 0	0 / 0	
Encephalopathy subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Encephalopathy		
	1 / 127 (0.79%)	0 / 127 (0.00%)	
	0 / 1	0 / 0	
	0 / 0	0 / 0	
Haemorrhagic transformation stroke subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Haemorrhagic transformation stroke		
	1 / 127 (0.79%)	0 / 127 (0.00%)	
	0 / 1	0 / 0	
	0 / 0	0 / 0	
Ischaemic stroke subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Ischaemic stroke		
	2 / 127 (1.57%)	0 / 127 (0.00%)	
	0 / 2	0 / 0	
	0 / 0	0 / 0	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Anaemia		
	1 / 127 (0.79%)	2 / 127 (1.57%)	
	1 / 1	1 / 2	
	0 / 0	0 / 0	
Granulocytopenia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Granulocytopenia		
	0 / 127 (0.00%)	1 / 127 (0.79%)	
	0 / 0	1 / 1	
	0 / 0	0 / 0	
Leukopenia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Leukopenia		
	0 / 127 (0.00%)	1 / 127 (0.79%)	
	0 / 0	1 / 1	
	0 / 0	0 / 0	
Microcytic anaemia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Microcytic anaemia		
	1 / 127 (0.79%)	0 / 127 (0.00%)	
	0 / 1	0 / 0	
	0 / 0	0 / 0	
Gastrointestinal disorders			

Diverticulum intestinal subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Diverticulum intestinal		
	1 / 127 (0.79%)	0 / 127 (0.00%)	
	0 / 1	0 / 0	
	0 / 0	0 / 0	
Gastritis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Gastritis		
	0 / 127 (0.00%)	1 / 127 (0.79%)	
	0 / 0	0 / 1	
	0 / 0	0 / 0	
Gastroesophageal reflux disease subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Gastroesophageal reflux disease		
	1 / 127 (0.79%)	0 / 127 (0.00%)	
	0 / 1	0 / 0	
	0 / 0	0 / 0	
Inguinal hernia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Inguinal hernia		
	0 / 127 (0.00%)	1 / 127 (0.79%)	
	0 / 0	0 / 1	
	0 / 0	0 / 0	
Hepatobiliary disorders Cholelithiasis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Cholelithiasis		
	1 / 127 (0.79%)	0 / 127 (0.00%)	
	0 / 2	0 / 0	
	0 / 0	0 / 0	
Cholecystitis acute subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Cholecystitis acute		
	1 / 127 (0.79%)	0 / 127 (0.00%)	
	0 / 1	0 / 0	
	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders Skin ulcer subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Skin ulcer		
	0 / 127 (0.00%)	1 / 127 (0.79%)	
	0 / 0	0 / 2	
	0 / 0	0 / 0	
Umbilical haematoma subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Umbilical haematoma		
	1 / 127 (0.79%)	0 / 127 (0.00%)	
	0 / 1	0 / 0	
	0 / 0	0 / 0	

Renal and urinary disorders			
Acute kidney injury	Additional description: Acute kidney injury		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma	Additional description: Bladder transitional cell carcinoma		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urinary	Additional description: Calculus urinary		
subjects affected / exposed	1 / 127 (0.79%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Bursitis	Additional description: Bursitis		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion	Additional description: Intervertebral disc protrusion		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis	Additional description: Osteoarthritis		
subjects affected / exposed	0 / 127 (0.00%)	2 / 127 (1.57%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid arthritis	Additional description: Rheumatoid arthritis		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Appendicitis	Additional description: Appendicitis		

subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
COVID-19	Additional description: COVID-19		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Cholangitis infective	Additional description: Cholangitis infective		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Diverticulitis	Additional description: Diverticulitis		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Pneumonia	Additional description: Pneumonia		
subjects affected / exposed	3 / 127 (2.36%)	3 / 127 (2.36%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 2	
-----			
Pneumonia viral	Additional description: Pneumonia viral		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Pseudomembranous colitis	Additional description: Pseudomembranous colitis		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Pyelonephritis acute	Additional description: Pyelonephritis acute		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Sepsis	Additional description: Sepsis		

subjects affected / exposed	1 / 127 (0.79%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Septic shock	Additional description: Septic shock		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis	Additional description: Sinusitis		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tuberculosis	Additional description: Tuberculosis		
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hyponatraemia	Additional description: Hyponatraemia		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	AOP2014	Control	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	115 / 127 (90.55%)	117 / 127 (92.13%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adrenal adenoma	Additional description: Adrenal adenoma		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences (all)	0	1	
Angiolipoma	Additional description: Angiolipoma		
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)	
occurrences (all)	0	1	
Adrenal neoplasm	Additional description: Adrenal neoplasm		

subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Angiomyolipoma	Additional description: Angiomyolipoma		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Benign neoplasm of thyroid gland	Additional description: Benign neoplasm of thyroid gland		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Bile duct cancer	Additional description: Bile duct cancer		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Blepharal papilloma	Additional description: Blepharal papilloma		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Colon adenoma	Additional description: Colon adenoma		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Fibrous histiocytoma	Additional description: Fibrous histiocytoma		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 2	
Haemangioma of liver	Additional description: Haemangioma of liver		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	
Intestinal adenocarcinoma	Additional description: Intestinal adenocarcinoma		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Keratoacanthoma	Additional description: Keratoacanthoma		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Lipoma	Additional description: Lipoma		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Myelofibrosis	Additional description: Myelofibrosis		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Primary myelofibrosis	Additional description: Primary myelofibrosis		

subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Prostate cancer	Additional description: Prostate cancer		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Prostatic adenoma	Additional description: Prostatic adenoma		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Uterine leiomyoma	Additional description: Uterine leiomyoma		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Vascular disorders	Additional description: Aneurysm		
Aneurysm	Additional description: Aneurysm		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Aortic stenosis	Additional description: Aortic stenosis		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	
Blood pressure fluctuation	Additional description: Blood pressure fluctuation		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	0 / 127 (0.00%) 0	
Circulatory collapse	Additional description: Circulatory collapse		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 3	0 / 127 (0.00%) 0	
Erythromelalgia	Additional description: Erythromelalgia		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 2	1 / 127 (0.79%) 1	
Femoral artery occlusion	Additional description: Femoral artery occlusion		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Haematoma	Additional description: Haematoma		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	4 / 127 (3.15%) 5	
Hypertension	Additional description: Hypertension		
subjects affected / exposed occurrences (all)	7 / 127 (5.51%) 12	12 / 127 (9.45%) 14	

Hypertensive crisis subjects affected / exposed occurrences (all)	Additional description: Hypertensive crisis	
	3 / 127 (2.36%) 3	1 / 127 (0.79%) 1
Hypotension subjects affected / exposed occurrences (all)	Additional description: Hypotension	
	3 / 127 (2.36%) 3	1 / 127 (0.79%) 1
Peripheral arterial occlusive disease subjects affected / exposed occurrences (all)	Additional description: Peripheral arterial occlusive disease	
	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1
Peripheral artery stenosis subjects affected / exposed occurrences (all)	Additional description: Peripheral artery stenosis	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Peripheral circulatory failure subjects affected / exposed occurrences (all)	Additional description: Peripheral circulatory failure	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Peripheral coldness subjects affected / exposed occurrences (all)	Additional description: Peripheral coldness	
	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1
Phlebitis subjects affected / exposed occurrences (all)	Additional description: Phlebitis	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Raynaud's phenomenon subjects affected / exposed occurrences (all)	Additional description: Raynaud's phenomenon	
	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1
Subclavian steal syndrome subjects affected / exposed occurrences (all)	Additional description: Subclavian steal syndrome	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Thrombophlebitis subjects affected / exposed occurrences (all)	Additional description: Thrombophlebitis	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Varicose vein subjects affected / exposed occurrences (all)	Additional description: Varicose vein	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Vascular pain subjects affected / exposed occurrences (all)	Additional description: Vascular pain	
	1 / 127 (0.79%) 1	2 / 127 (1.57%) 2

Venous thrombosis limb subjects affected / exposed occurrences (all)	Additional description: Venous thrombosis limb	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Surgical and medical procedures Blepharoplasty subjects affected / exposed occurrences (all)	Additional description: Blepharoplasty	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Carpal tunnel decompression subjects affected / exposed occurrences (all)	Additional description: Carpal tunnel decompression	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Cataract operation subjects affected / exposed occurrences (all)	Additional description: Cataract operation	
	2 / 127 (1.57%) 3	5 / 127 (3.94%) 6
Endocervical curettage subjects affected / exposed occurrences (all)	Additional description: Endocervical curettage	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Eye operation subjects affected / exposed occurrences (all)	Additional description: Eye operation	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Intraocular lens implant subjects affected / exposed occurrences (all)	Additional description: Intraocular lens implant	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Maxillofacial operation subjects affected / exposed occurrences (all)	Additional description: Maxillofacial operation	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Ovarian cystectomy subjects affected / exposed occurrences (all)	Additional description: Ovarian cystectomy	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Peripheral endarterectomy subjects affected / exposed occurrences (all)	Additional description: Peripheral endarterectomy	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Polypectomy subjects affected / exposed occurrences (all)	Additional description: Polypectomy	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Proctectomy	Additional description: Proctectomy	

subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Prostatic operation	Additional description: Prostatic operation		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Skin neoplasm excision	Additional description: Skin neoplasm excision		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Tooth extraction	Additional description: Tooth extraction		
subjects affected / exposed occurrences (all)	6 / 127 (4.72%) 7	2 / 127 (1.57%) 2	
General disorders and administration site conditions			
Asthenia	Additional description: Asthenia		
subjects affected / exposed occurrences (all)	11 / 127 (8.66%) 20	7 / 127 (5.51%) 24	
Axillary pain	Additional description: Axillary pain		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Chest discomfort	Additional description: Chest discomfort		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Chest pain	Additional description: Chest pain		
subjects affected / exposed occurrences (all)	5 / 127 (3.94%) 5	1 / 127 (0.79%) 1	
Chills	Additional description: Chills		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 3	2 / 127 (1.57%) 2	
Condition aggravated	Additional description: Condition aggravated		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Cyst	Additional description: Cyst		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Drug intolerance	Additional description: Drug intolerance		

subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Facial pain	Additional description: Facial pain		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 4	0 / 127 (0.00%) 0	
Fatigue	Additional description: Fatigue		
subjects affected / exposed occurrences (all)	17 / 127 (13.39%) 47	21 / 127 (16.54%) 27	
Feeling cold	Additional description: Feeling cold		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 3	
Impaired healing	Additional description: Impaired healing		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 2	0 / 127 (0.00%) 0	
Inflammation	Additional description: Inflammation		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	2 / 127 (1.57%) 2	
Influenza like illness	Additional description: Influenza like illness		
subjects affected / exposed occurrences (all)	10 / 127 (7.87%) 16	3 / 127 (2.36%) 3	
Injection site erythema	Additional description: Injection site erythema		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Injection site haematoma	Additional description: Injection site haematoma		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 2	0 / 127 (0.00%) 0	
Injection site pain	Additional description: Injection site pain		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 4	0 / 127 (0.00%) 0	
Injection site pruritus	Additional description: Injection site pruritus		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 2	0 / 127 (0.00%) 0	
Injection site reaction	Additional description: Injection site reaction		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Injection site warmth	Additional description: Injection site warmth		

subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Mucosal inflammation	Additional description: Mucosal inflammation		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 3	1 / 127 (0.79%) 2	
Non-cardiac chest pain	Additional description: Non-cardiac chest pain		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Oedema peripheral	Additional description: Oedema peripheral		
subjects affected / exposed occurrences (all)	5 / 127 (3.94%) 5	4 / 127 (3.15%) 4	
Pain	Additional description: Pain		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	4 / 127 (3.15%) 5	
Peripheral swelling	Additional description: Peripheral swelling		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Puncture site pain	Additional description: Puncture site pain		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Pyrexia	Additional description: Pyrexia		
subjects affected / exposed occurrences (all)	13 / 127 (10.24%) 21	6 / 127 (4.72%) 7	
Sensation of foreign body	Additional description: Sensation of foreign body		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Soft tissue inflammation	Additional description: Soft tissue inflammation		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Thirst	Additional description: Thirst		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Immune system disorders	Additional description: Allergy to arthropod sting		
Allergy to arthropod sting subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	

Drug hypersensitivity subjects affected / exposed occurrences (all)	Additional description: Drug hypersensitivity	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Hypersensitivity subjects affected / exposed occurrences (all)	Additional description: Hypersensitivity	
	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2
Sarcoidosis subjects affected / exposed occurrences (all)	Additional description: Sarcoidosis	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Seasonal allergy subjects affected / exposed occurrences (all)	Additional description: Seasonal allergy	
	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1
Social circumstances		
Stress at work subjects affected / exposed occurrences (all)	Additional description: Stress at work	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Reproductive system and breast disorders		
Acquired phimosis subjects affected / exposed occurrences (all)	Additional description: Acquired phimosis	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Amenorrhoea subjects affected / exposed occurrences (all)	Additional description: Amenorrhoea	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Benign prostatic hyperplasia subjects affected / exposed occurrences (all)	Additional description: Benign prostatic hyperplasia	
	5 / 127 (3.94%) 5	0 / 127 (0.00%) 0
Breast disorder subjects affected / exposed occurrences (all)	Additional description: Breast disorder	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Breast pain subjects affected / exposed occurrences (all)	Additional description: Breast pain	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Endometrial dysplasia subjects affected / exposed occurrences (all)	Additional description: Endometrial dysplasia	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Erectile dysfunction	Additional description: Erectile dysfunction	

subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	0 / 127 (0.00%) 0	
Fibrocystic breast disease	Additional description: Fibrocystic breast disease		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Haematospermia	Additional description: Haematospermia		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Metrorrhagia	Additional description: Metrorrhagia		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Menstruation irregular	Additional description: Menstruation irregular		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Ovarian cyst	Additional description: Ovarian cyst		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Prostatitis	Additional description: Prostatitis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Uterine cervical erosion	Additional description: Uterine cervical erosion		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Uterine haemorrhage	Additional description: Uterine haemorrhage		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Vaginal haemorrhage	Additional description: Vaginal haemorrhage		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders			
Asthma	Additional description: Asthma		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Cough	Additional description: Cough		

subjects affected / exposed occurrences (all)	11 / 127 (8.66%) 19	11 / 127 (8.66%) 12	
Dysphonia	Additional description: Dysphonia		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Dyspnoea	Additional description: Dyspnoea		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	2 / 127 (1.57%) 2	
Dyspnoea exertional	Additional description: Dyspnoea exertional		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 3	0 / 127 (0.00%) 0	
Epistaxis	Additional description: Epistaxis		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 3	2 / 127 (1.57%) 2	
Increased bronchial secretion	Additional description: Increased bronchial secretion		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Lung infiltration	Additional description: Lung infiltration		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Oropharyngeal pain	Additional description: Oropharyngeal pain		
subjects affected / exposed occurrences (all)	7 / 127 (5.51%) 10	3 / 127 (2.36%) 3	
Pneumonitis	Additional description: Pneumonitis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Pulmonary hypertension	Additional description: Pulmonary hypertension		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	2 / 127 (1.57%) 2	
Pulmonary microemboli	Additional description: Pulmonary microemboli		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Rales	Additional description: Rales		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Rhinitis allergic	Additional description: Rhinitis allergic		

subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	
Rhinitis atrophic	Additional description: Rhinitis atrophic		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 2	0 / 127 (0.00%) 0	
Sneezing	Additional description: Sneezing		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Throat irritation	Additional description: Throat irritation		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Psychiatric disorders	Additional description: Affective disorder		
Affective disorder subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 3	1 / 127 (0.79%) 1	
Agitation	Additional description: Agitation		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Anxiety	Additional description: Anxiety		
subjects affected / exposed occurrences (all)	5 / 127 (3.94%) 8	4 / 127 (3.15%) 4	
Anxiety disorder	Additional description: Anxiety disorder		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Apathy	Additional description: Apathy		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Depressed mood	Additional description: Depressed mood		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Depression	Additional description: Depression		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 3	4 / 127 (3.15%) 4	
Emotional distress	Additional description: Emotional distress		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	

Hallucination subjects affected / exposed occurrences (all)	Additional description: Hallucination	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Insomnia subjects affected / exposed occurrences (all)	Additional description: Insomnia	
	4 / 127 (3.15%) 4	7 / 127 (5.51%) 9
Irritability subjects affected / exposed occurrences (all)	Additional description: Irritability	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Libido increased subjects affected / exposed occurrences (all)	Additional description: Libido increased	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 3
Mood altered subjects affected / exposed occurrences (all)	Additional description: Mood altered	
	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1
Mood swings subjects affected / exposed occurrences (all)	Additional description: Mood swings	
	2 / 127 (1.57%) 3	0 / 127 (0.00%) 0
Nervousness subjects affected / exposed occurrences (all)	Additional description: Nervousness	
	2 / 127 (1.57%) 3	0 / 127 (0.00%) 0
Panic attack subjects affected / exposed occurrences (all)	Additional description: Panic attack	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Restlessness subjects affected / exposed occurrences (all)	Additional description: Restlessness	
	2 / 127 (1.57%) 2	0 / 127 (0.00%) 0
Sleep disorder subjects affected / exposed occurrences (all)	Additional description: Sleep disorder	
	3 / 127 (2.36%) 3	2 / 127 (1.57%) 2
Hepatobiliary disorders		
Biliary colic subjects affected / exposed occurrences (all)	Additional description: Biliary colic	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Cholecystitis	Additional description: Cholecystitis	

subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Cholecystitis chronic	Additional description: Cholecystitis chronic		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	0 / 127 (0.00%) 0	
Cholelithiasis	Additional description: Cholelithiasis		
subjects affected / exposed occurrences (all)	4 / 127 (3.15%) 4	3 / 127 (2.36%) 3	
Gallbladder cholesterolosis	Additional description: Gallbladder cholesterolosis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Gallbladder disorder	Additional description: Gallbladder disorder		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	
Gallbladder polyp	Additional description: Gallbladder polyp		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Hepatic cyst	Additional description: Hepatic cyst		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 3	0 / 127 (0.00%) 0	
Hepatic steatosis	Additional description: Hepatic steatosis		
subjects affected / exposed occurrences (all)	4 / 127 (3.15%) 4	1 / 127 (0.79%) 1	
Hepatitis toxic	Additional description: Hepatitis toxic		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 4	0 / 127 (0.00%) 0	
Hepatomegaly	Additional description: Hepatomegaly		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	
Hepatosplenomegaly	Additional description: Hepatosplenomegaly		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Hyperbilirubinaemia	Additional description: Hyperbilirubinaemia		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 2	
Liver disorder	Additional description: Liver disorder		

subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 3	2 / 127 (1.57%) 2	
Pneumobilia	Additional description: Pneumobilia		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Portal hypertension	Additional description: Portal hypertension		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Steatohepatitis	Additional description: Steatohepatitis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Investigations			
Alanine aminotransferase increased	Additional description: Alanine aminotransferase increased		
subjects affected / exposed occurrences (all)	19 / 127 (14.96%) 40	2 / 127 (1.57%) 2	
Anti-thyroid antibody positive	Additional description: Anti-thyroid antibody positive		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 6	0 / 127 (0.00%) 0	
Antinuclear antibody increased	Additional description: Antinuclear antibody increased		
subjects affected / exposed occurrences (all)	4 / 127 (3.15%) 4	3 / 127 (2.36%) 3	
Aspartate aminotransferase increased	Additional description: Aspartate aminotransferase increased		
subjects affected / exposed occurrences (all)	17 / 127 (13.39%) 27	2 / 127 (1.57%) 2	
Blood alkaline phosphatase increased	Additional description: Blood alkaline phosphatase increased		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 6	1 / 127 (0.79%) 1	
Blood bilirubin increased	Additional description: Blood bilirubin increased		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	
Blood creatine phosphokinase increased	Additional description: Blood creatine phosphokinase increased		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Blood creatinine increased	Additional description: Blood creatinine increased		

subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 6	1 / 127 (0.79%) 1	
Blood fibrinogen decreased subjects affected / exposed occurrences (all)	Additional description: Blood fibrinogen decreased		
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 2	
Blood glucose increased subjects affected / exposed occurrences (all)	Additional description: Blood glucose increased		
	0 / 127 (0.00%) 0	3 / 127 (2.36%) 3	
Blood iron decreased subjects affected / exposed occurrences (all)	Additional description: Blood iron decreased		
	1 / 127 (0.79%) 1	4 / 127 (3.15%) 4	
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	Additional description: Blood lactate dehydrogenase increased		
	3 / 127 (2.36%) 4	2 / 127 (1.57%) 2	
Blood phosphorus decreased subjects affected / exposed occurrences (all)	Additional description: Blood phosphorus decreased		
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Blood potassium increased subjects affected / exposed occurrences (all)	Additional description: Blood potassium increased		
	1 / 127 (0.79%) 1	2 / 127 (1.57%) 2	
Blood potassium decreased subjects affected / exposed occurrences (all)	Additional description: Blood potassium decreased		
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Blood pressure abnormal subjects affected / exposed occurrences (all)	Additional description: Blood pressure abnormal		
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Blood pressure diastolic increased subjects affected / exposed occurrences (all)	Additional description: Blood pressure diastolic increased		
	1 / 127 (0.79%) 2	0 / 127 (0.00%) 0	
Blood pressure systolic increased subjects affected / exposed occurrences (all)	Additional description: Blood pressure systolic increased		
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Blood pressure increased subjects affected / exposed occurrences (all)	Additional description: Blood pressure increased		
	1 / 127 (0.79%) 1	1 / 127 (0.79%) 2	

Blood thyroid stimulating hormone increased	Additional description: Blood thyroid stimulating hormone increased	
subjects affected / exposed	5 / 127 (3.94%)	1 / 127 (0.79%)
occurrences (all)	6	4
Blood triglycerides increased	Additional description: Blood triglycerides increased	
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)
occurrences (all)	0	1
Blood urea increased	Additional description: Blood urea increased	
subjects affected / exposed	2 / 127 (1.57%)	1 / 127 (0.79%)
occurrences (all)	7	1
Blood uric acid increased	Additional description: Blood uric acid increased	
subjects affected / exposed	4 / 127 (3.15%)	2 / 127 (1.57%)
occurrences (all)	4	2
Body temperature decreased	Additional description: Body temperature decreased	
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)
occurrences (all)	1	0
Body temperature increased	Additional description: Body temperature increased	
subjects affected / exposed	3 / 127 (2.36%)	1 / 127 (0.79%)
occurrences (all)	3	1
Colonoscopy	Additional description: Colonoscopy	
subjects affected / exposed	2 / 127 (1.57%)	0 / 127 (0.00%)
occurrences (all)	2	0
Computerised tomogram	Additional description: Computerised tomogram	
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)
occurrences (all)	0	1
Eastern Cooperative Oncology Group performance status worsened	Additional description: Eastern Cooperative Oncology Group performance status worsened	
subjects affected / exposed	1 / 127 (0.79%)	1 / 127 (0.79%)
occurrences (all)	1	1
Electrocardiogram PR prolongation	Additional description: Electrocardiogram PR prolongation	
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)
occurrences (all)	1	0
Ejection fraction decreased	Additional description: Ejection fraction decreased	
subjects affected / exposed	4 / 127 (3.15%)	1 / 127 (0.79%)
occurrences (all)	4	1
Electrocardiogram QT interval abnormal	Additional description: Electrocardiogram QT interval abnormal	

subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Electrocardiogram QT prolonged	Additional description: Electrocardiogram QT prolonged		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Endoscopy upper gastrointestinal tract	Additional description: Endoscopy upper gastrointestinal tract		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Gamma-glutamyltransferase increased	Additional description: Gamma-glutamyltransferase increased		
subjects affected / exposed occurrences (all)	28 / 127 (22.05%) 91	5 / 127 (3.94%) 5	
Haematocrit decreased	Additional description: Haematocrit decreased		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	4 / 127 (3.15%) 5	
Haematocrit increased	Additional description: Haematocrit increased		
subjects affected / exposed occurrences (all)	6 / 127 (4.72%) 11	5 / 127 (3.94%) 7	
Haemoglobin decreased	Additional description: Haemoglobin decreased		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Hepatic enzyme increased	Additional description: Hepatic enzyme increased		
subjects affected / exposed occurrences (all)	8 / 127 (6.30%) 16	1 / 127 (0.79%) 2	
Lipase increased	Additional description: Lipase increased		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 7	2 / 127 (1.57%) 2	
Lymphocyte count decreased	Additional description: Lymphocyte count decreased		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Magnetic resonance imaging	Additional description: Magnetic resonance imaging		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Mean cell volume increased	Additional description: Mean cell volume increased		

subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	
Neutrophil count increased	Additional description: Neutrophil count increased		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Nitrite urine present	Additional description: Nitrite urine present		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Platelet count decreased	Additional description: Platelet count decreased		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 5	12 / 127 (9.45%) 21	
Platelet count increased	Additional description: Platelet count increased		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 3	2 / 127 (1.57%) 2	
Scan with contrast	Additional description: Scan with contrast		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Serum ferritin decreased	Additional description: Serum ferritin decreased		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Transaminases increased	Additional description: Transaminases increased		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Transferrin decreased	Additional description: Transferrin decreased		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 3	2 / 127 (1.57%) 3	
Visual acuity tests abnormal	Additional description: Visual acuity tests abnormal		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Urine analysis abnormal	Additional description: Urine analysis abnormal		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Weight decreased	Additional description: Weight decreased		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 4	1 / 127 (0.79%) 1	
White blood cell count decreased	Additional description: White blood cell count decreased		

subjects affected / exposed occurrences (all)	5 / 127 (3.94%) 12	5 / 127 (3.94%) 9	
White blood cell count increased	Additional description: White blood cell count increased		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	
White blood cells urine positive	Additional description: White blood cells urine positive		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Injury, poisoning and procedural complications			
Accidental overdose	Additional description: Accidental overdose		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Animal bite	Additional description: Animal bite		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Anaemia postoperative	Additional description: Anaemia postoperative		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Ankle fracture	Additional description: Ankle fracture		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Arthropod bite	Additional description: Arthropod bite		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Contrast media reaction	Additional description: Contrast media reaction		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Contusion	Additional description: Contusion		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	3 / 127 (2.36%) 5	
Fall	Additional description: Fall		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Foot fracture	Additional description: Foot fracture		

subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	0 / 127 (0.00%) 0	
Additional description: Gastrointestinal disorder postoperative			
Gastrointestinal disorder postoperative subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Additional description: Forearm fracture			
Forearm fracture subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Additional description: Incisional hernia			
Incisional hernia subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Additional description: Joint dislocation			
Joint dislocation subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Additional description: Joint injury			
Joint injury subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Additional description: Ligament sprain			
Ligament sprain subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	0 / 127 (0.00%) 0	
Additional description: Muscle strain			
Muscle strain subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Additional description: Limb injury			
Limb injury subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	2 / 127 (1.57%) 2	
Additional description: Overdose			
Overdose subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Additional description: Postoperative wound complication			
Postoperative wound complication subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Additional description: Retinal injury			
Retinal injury subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	

Road traffic accident subjects affected / exposed occurrences (all)	Additional description: Road traffic accident		
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Thermal burn subjects affected / exposed occurrences (all)	Additional description: Thermal burn		
	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Subcutaneous haematoma subjects affected / exposed occurrences (all)	Additional description: Subcutaneous haematoma		
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Tibia fracture subjects affected / exposed occurrences (all)	Additional description: Tibia fracture		
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Traumatic haematoma subjects affected / exposed occurrences (all)	Additional description: Traumatic haematoma		
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Wound subjects affected / exposed occurrences (all)	Additional description: Wound		
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Congenital, familial and genetic disorders			
Cataract congenital subjects affected / exposed occurrences (all)	Additional description: Cataract congenital		
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Marfan's syndrome subjects affected / exposed occurrences (all)	Additional description: Marfan's syndrome		
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Cardiac disorders			
Angina pectoris subjects affected / exposed occurrences (all)	Additional description: Angina pectoris		
	2 / 127 (1.57%) 4	0 / 127 (0.00%) 0	
Aortic valve calcification subjects affected / exposed occurrences (all)	Additional description: Aortic valve calcification		
	0 / 127 (0.00%) 0	3 / 127 (2.36%) 3	
Arrhythmia subjects affected / exposed occurrences (all)	Additional description: Arrhythmia		
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Atrial fibrillation	Additional description: Atrial fibrillation		

subjects affected / exposed occurrences (all)	4 / 127 (3.15%) 4	4 / 127 (3.15%) 14	
Atrial flutter	Additional description: Atrial flutter		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Atrioventricular block second degree	Additional description: Atrioventricular block second degree		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Bradycardia	Additional description: Bradycardia		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Bundle branch block left	Additional description: Bundle branch block left		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Cardiac failure	Additional description: Cardiac failure		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 3	1 / 127 (0.79%) 1	
Cardiac failure chronic	Additional description: Cardiac failure chronic		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 3	0 / 127 (0.00%) 0	
Cyanosis	Additional description: Cyanosis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Dilatation ventricular	Additional description: Dilatation ventricular		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Extrasystoles	Additional description: Extrasystoles		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Heart valve incompetence	Additional description: Heart valve incompetence		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Hepatojugular reflux	Additional description: Hepatojugular reflux		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Intracardiac thrombus	Additional description: Intracardiac thrombus		

subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Mitral valve calcification	Additional description: Mitral valve calcification		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	
Mitral valve incompetence	Additional description: Mitral valve incompetence		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	2 / 127 (1.57%) 2	
Pericardial cyst	Additional description: Pericardial cyst		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Palpitations	Additional description: Palpitations		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 4	1 / 127 (0.79%) 1	
Right atrial enlargement	Additional description: Right atrial enlargement		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Sinoatrial block	Additional description: Sinoatrial block		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Sinus tachycardia	Additional description: Sinus tachycardia		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Supraventricular extrasystoles	Additional description: Supraventricular extrasystoles		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 3	
Tachycardia	Additional description: Tachycardia		
subjects affected / exposed occurrences (all)	4 / 127 (3.15%) 4	2 / 127 (1.57%) 3	
Tricuspid valve incompetence	Additional description: Tricuspid valve incompetence		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Ventricular extrasystoles	Additional description: Ventricular extrasystoles		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	2 / 127 (1.57%) 5	
Ventricular tachycardia	Additional description: Ventricular tachycardia		

subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Nervous system disorders			
Additional description: Burning sensation			
Burning sensation subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 2	
Additional description: Carotid artery stenosis			
Carotid artery stenosis subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Additional description: Diabetic neuropathy			
Diabetic neuropathy subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Additional description: Carpal tunnel syndrome			
Carpal tunnel syndrome subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Additional description: Dizziness			
Dizziness subjects affected / exposed occurrences (all)	14 / 127 (11.02%) 25	11 / 127 (8.66%) 16	
Additional description: Dysgeusia			
Dysgeusia subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	
Additional description: Encephalopathy			
Encephalopathy subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Additional description: Head discomfort			
Head discomfort subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Additional description: Headache			
Headache subjects affected / exposed occurrences (all)	16 / 127 (12.60%) 34	18 / 127 (14.17%) 28	
Additional description: Hypoaesthesia			
Hypoaesthesia subjects affected / exposed occurrences (all)	4 / 127 (3.15%) 6	0 / 127 (0.00%) 0	
Additional description: Intercostal neuralgia			
Intercostal neuralgia subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	

Loss of consciousness subjects affected / exposed occurrences (all)	Additional description: Loss of consciousness	
	2 / 127 (1.57%) 2	0 / 127 (0.00%) 0
Lumbar radiculopathy subjects affected / exposed occurrences (all)	Additional description: Lumbar radiculopathy	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 2
Memory impairment subjects affected / exposed occurrences (all)	Additional description: Memory impairment	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Migraine subjects affected / exposed occurrences (all)	Additional description: Migraine	
	4 / 127 (3.15%) 4	0 / 127 (0.00%) 0
Migraine with aura subjects affected / exposed occurrences (all)	Additional description: Migraine with aura	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Neuralgia subjects affected / exposed occurrences (all)	Additional description: Neuralgia	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Neuropathy peripheral subjects affected / exposed occurrences (all)	Additional description: Neuropathy peripheral	
	2 / 127 (1.57%) 2	0 / 127 (0.00%) 0
Paraesthesia subjects affected / exposed occurrences (all)	Additional description: Paraesthesia	
	0 / 127 (0.00%) 0	5 / 127 (3.94%) 6
Parosmia subjects affected / exposed occurrences (all)	Additional description: Parosmia	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Post herpetic neuralgia subjects affected / exposed occurrences (all)	Additional description: Post herpetic neuralgia	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Peripheral nerve lesion subjects affected / exposed occurrences (all)	Additional description: Peripheral nerve lesion	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Radiculopathy subjects affected / exposed occurrences (all)	Additional description: Radiculopathy	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0

Sciatica	Additional description: Sciatica	
subjects affected / exposed	2 / 127 (1.57%)	0 / 127 (0.00%)
occurrences (all)	2	0
Sinus headache	Additional description: Sinus headache	
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)
occurrences (all)	0	1
Somnolence	Additional description: Somnolence	
subjects affected / exposed	2 / 127 (1.57%)	1 / 127 (0.79%)
occurrences (all)	2	1
Tension headache	Additional description: Tension headache	
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)
occurrences (all)	0	1
Tremor	Additional description: Tremor	
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)
occurrences (all)	0	1
Trigeminal neuritis	Additional description: Trigeminal neuritis	
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)
occurrences (all)	0	1
Blood and lymphatic system disorders	Additional description: Anaemia	
Anaemia	Additional description: Anaemia	
subjects affected / exposed	21 / 127 (16.54%)	37 / 127 (29.13%)
occurrences (all)	41	67
Blood loss anaemia	Additional description: Blood loss anaemia	
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)
occurrences (all)	1	0
Cytopenia	Additional description: Cytopenia	
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)
occurrences (all)	1	0
Granulocytopenia	Additional description: Granulocytopenia	
subjects affected / exposed	1 / 127 (0.79%)	1 / 127 (0.79%)
occurrences (all)	1	1
Iron deficiency anaemia	Additional description: Iron deficiency anaemia	
subjects affected / exposed	4 / 127 (3.15%)	0 / 127 (0.00%)
occurrences (all)	9	0
Leukocytosis	Additional description: Leukocytosis	

subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	4 / 127 (3.15%) 5	
Leukopenia	Additional description: Leukopenia		
subjects affected / exposed occurrences (all)	27 / 127 (21.26%) 148	31 / 127 (24.41%) 82	
Lymphadenitis	Additional description: Lymphadenitis		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Lymphadenopathy	Additional description: Lymphadenopathy		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	3 / 127 (2.36%) 3	
Microcytic anaemia	Additional description: Microcytic anaemia		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 2	0 / 127 (0.00%) 0	
Neutropenia	Additional description: Neutropenia		
subjects affected / exposed occurrences (all)	6 / 127 (4.72%) 7	7 / 127 (5.51%) 14	
Pancytopenia	Additional description: Pancytopenia		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 4	0 / 127 (0.00%) 0	
Polycythaemia	Additional description: Polycythaemia		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Splenic cyst	Additional description: Splenic cyst		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Splenic infarction	Additional description: Splenic infarction		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Splenomegaly	Additional description: Splenomegaly		
subjects affected / exposed occurrences (all)	13 / 127 (10.24%) 13	8 / 127 (6.30%) 8	
Thrombocytopenia	Additional description: Thrombocytopenia		
subjects affected / exposed occurrences (all)	28 / 127 (22.05%) 81	37 / 127 (29.13%) 101	
Thrombocytosis	Additional description: Thrombocytosis		

subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 2	3 / 127 (2.36%) 4	
Ear and labyrinth disorders	Additional description: Ear and labyrinth disorders		
Cerumen impaction subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Deafness neurosensory subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 2	
Ear discomfort subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Tinnitus subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 8	1 / 127 (0.79%) 1	
Vertigo subjects affected / exposed occurrences (all)	5 / 127 (3.94%) 5	8 / 127 (6.30%) 9	
Vestibular disorder subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Eye disorders	Additional description: Eye disorders		
Age-related macular degeneration subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Asthenopia subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Blepharitis subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Blepharochalasis subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Cataract	Additional description: Cataract		

subjects affected / exposed occurrences (all)	7 / 127 (5.51%) 8	3 / 127 (2.36%) 4	
Chalazion	Additional description: Chalazion		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	
Conjunctival haemorrhage	Additional description: Conjunctival haemorrhage		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Corneal opacity	Additional description: Corneal opacity		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Diabetic retinopathy	Additional description: Diabetic retinopathy		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Dry eye	Additional description: Dry eye		
subjects affected / exposed occurrences (all)	7 / 127 (5.51%) 7	3 / 127 (2.36%) 3	
Ectropion	Additional description: Ectropion		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Eye haemorrhage	Additional description: Eye haemorrhage		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Eye inflammation	Additional description: Eye inflammation		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Eye irritation	Additional description: Eye irritation		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Eye pain	Additional description: Eye pain		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Eye pruritus	Additional description: Eye pruritus		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Eyelid ptosis	Additional description: Eyelid ptosis		

subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Eyelid skin dryness	Additional description: Eyelid skin dryness		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Iridocyclitis	Additional description: Iridocyclitis		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Keratopathy	Additional description: Keratopathy		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Maculopathy	Additional description: Maculopathy		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Myopia	Additional description: Myopia		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Posterior capsule opacification	Additional description: Posterior capsule opacification		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Presbyopia	Additional description: Presbyopia		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	0 / 127 (0.00%) 0	
Retinopathy	Additional description: Retinopathy		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	1 / 127 (0.79%) 1	
Retinopathy hypertensive	Additional description: Retinopathy hypertensive		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Vision blurred	Additional description: Vision blurred		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	0 / 127 (0.00%) 0	
Visual acuity reduced	Additional description: Visual acuity reduced		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 3	0 / 127 (0.00%) 0	
Vitreous haemorrhage	Additional description: Vitreous haemorrhage		

subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Gastrointestinal disorders	Additional description: Abdominal discomfort		
Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	
Abdominal distension subjects affected / exposed occurrences (all)	Additional description: Abdominal distension		
	2 / 127 (1.57%) 2	1 / 127 (0.79%) 2	
Abdominal pain subjects affected / exposed occurrences (all)	Additional description: Abdominal pain		
	8 / 127 (6.30%) 10	7 / 127 (5.51%) 14	
Abdominal pain upper subjects affected / exposed occurrences (all)	Additional description: Abdominal pain upper		
	5 / 127 (3.94%) 6	7 / 127 (5.51%) 12	
Abdominal wall disorder subjects affected / exposed occurrences (all)	Additional description: Abdominal wall disorder		
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Aphthous ulcer subjects affected / exposed occurrences (all)	Additional description: Aphthous ulcer		
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Bowel movement irregularity subjects affected / exposed occurrences (all)	Additional description: Bowel movement irregularity		
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Burning mouth syndrome subjects affected / exposed occurrences (all)	Additional description: Burning mouth syndrome		
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Chronic gastritis subjects affected / exposed occurrences (all)	Additional description: Chronic gastritis		
	0 / 127 (0.00%) 0	2 / 127 (1.57%) 3	
Colitis subjects affected / exposed occurrences (all)	Additional description: Colitis		
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 2	
Constipation subjects affected / exposed occurrences (all)	Additional description: Constipation		
	4 / 127 (3.15%) 6	6 / 127 (4.72%) 6	

Dental caries subjects affected / exposed occurrences (all)	Additional description: Dental caries	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	Additional description: Diarrhoea	
	11 / 127 (8.66%) 28	15 / 127 (11.81%) 29
Diverticulum intestinal subjects affected / exposed occurrences (all)	Additional description: Diverticulum intestinal	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Dry mouth subjects affected / exposed occurrences (all)	Additional description: Dry mouth	
	2 / 127 (1.57%) 2	1 / 127 (0.79%) 1
Duodenogastric reflux subjects affected / exposed occurrences (all)	Additional description: Duodenogastric reflux	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Dyspepsia subjects affected / exposed occurrences (all)	Additional description: Dyspepsia	
	6 / 127 (4.72%) 6	2 / 127 (1.57%) 6
Dysphagia subjects affected / exposed occurrences (all)	Additional description: Dysphagia	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Epigastric discomfort subjects affected / exposed occurrences (all)	Additional description: Epigastric discomfort	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Flatulence subjects affected / exposed occurrences (all)	Additional description: Flatulence	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Gastric disorder subjects affected / exposed occurrences (all)	Additional description: Gastric disorder	
	2 / 127 (1.57%) 2	1 / 127 (0.79%) 2
Gastritis subjects affected / exposed occurrences (all)	Additional description: Gastritis	
	4 / 127 (3.15%) 4	1 / 127 (0.79%) 3
Gastritis erosive subjects affected / exposed occurrences (all)	Additional description: Gastritis erosive	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0

Gastrointestinal angiodysplasia  
subjects affected / exposed  
occurrences (all)

Additional description: Gastrointestinal angiodysplasia

1 / 127 (0.79%)	0 / 127 (0.00%)
1	0

Gastrointestinal disorder  
subjects affected / exposed  
occurrences (all)

Additional description: Gastrointestinal disorder

1 / 127 (0.79%)	0 / 127 (0.00%)
1	0

Gastrointestinal motility disorder  
subjects affected / exposed  
occurrences (all)

Additional description: Gastrointestinal motility disorder

2 / 127 (1.57%)	0 / 127 (0.00%)
3	0

Gastrointestinal pain  
subjects affected / exposed  
occurrences (all)

Additional description: Gastrointestinal pain

0 / 127 (0.00%)	1 / 127 (0.79%)
0	1

Gastrointestinal scarring  
subjects affected / exposed  
occurrences (all)

Additional description: Gastrointestinal scarring

1 / 127 (0.79%)	0 / 127 (0.00%)
1	0

Gastroesophageal reflux disease  
subjects affected / exposed  
occurrences (all)

Additional description: Gastroesophageal reflux disease

5 / 127 (3.94%)	1 / 127 (0.79%)
5	1

Gastroesophageal sphincter  
insufficiency

Additional description: Gastroesophageal sphincter insufficiency

subjects affected / exposed  
occurrences (all)

0 / 127 (0.00%)	1 / 127 (0.79%)
0	1

Gingival bleeding  
subjects affected / exposed  
occurrences (all)

Additional description: Gingival bleeding

1 / 127 (0.79%)	2 / 127 (1.57%)
1	2

Gingival hypertrophy  
subjects affected / exposed  
occurrences (all)

Additional description: Gingival hypertrophy

1 / 127 (0.79%)	0 / 127 (0.00%)
1	0

Gingival pain  
subjects affected / exposed  
occurrences (all)

Additional description: Gingival pain

0 / 127 (0.00%)	1 / 127 (0.79%)
0	1

Gingival recession  
subjects affected / exposed  
occurrences (all)

Additional description: Gingival recession

1 / 127 (0.79%)	0 / 127 (0.00%)
1	0

Gingivitis ulcerative

Additional description: Gingivitis ulcerative

subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Haematemesis	Additional description: Haematemesis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Haematochezia	Additional description: Haematochezia		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 2	0 / 127 (0.00%) 0	
Haemorrhoidal haemorrhage	Additional description: Haemorrhoidal haemorrhage		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Haemorrhoids	Additional description: Haemorrhoids		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 4	1 / 127 (0.79%) 1	
Inguinal hernia	Additional description: Inguinal hernia		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Intra-abdominal haematoma	Additional description: Intra-abdominal haematoma		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Irritable bowel syndrome	Additional description: Irritable bowel syndrome		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Mouth swelling	Additional description: Mouth swelling		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Nausea	Additional description: Nausea		
subjects affected / exposed occurrences (all)	4 / 127 (3.15%) 6	17 / 127 (13.39%) 21	
Oesophagitis	Additional description: Oesophagitis		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Pancreatitis	Additional description: Pancreatitis		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Pancreatitis chronic	Additional description: Pancreatitis chronic		

subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 3	1 / 127 (0.79%) 1	
Paraesthesia oral	Additional description: Paraesthesia oral		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Rectal fissure	Additional description: Rectal fissure		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Rectal haemorrhage	Additional description: Rectal haemorrhage		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	2 / 127 (1.57%) 2	
Rectal polyp	Additional description: Rectal polyp		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Reflux gastritis	Additional description: Reflux gastritis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Stomatitis	Additional description: Stomatitis		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	2 / 127 (1.57%) 5	
Toothache	Additional description: Toothache		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Truncus coeliacus thrombosis	Additional description: Truncus coeliacus thrombosis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Vomiting	Additional description: Vomiting		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 3	6 / 127 (4.72%) 7	
Skin and subcutaneous tissue disorders			
Acanthosis nigricans	Additional description: Acanthosis nigricans		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Actinic keratosis	Additional description: Actinic keratosis		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	

Alopecia	Additional description: Alopecia	
subjects affected / exposed	6 / 127 (4.72%)	0 / 127 (0.00%)
occurrences (all)	9	0
Blood blister	Additional description: Blood blister	
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)
occurrences (all)	1	0
Dermal cyst	Additional description: Dermal cyst	
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)
occurrences (all)	1	0
Dermatitis	Additional description: Dermatitis	
subjects affected / exposed	0 / 127 (0.00%)	2 / 127 (1.57%)
occurrences (all)	0	2
Dermatitis acneiform	Additional description: Dermatitis acneiform	
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)
occurrences (all)	1	0
Dry skin	Additional description: Dry skin	
subjects affected / exposed	2 / 127 (1.57%)	5 / 127 (3.94%)
occurrences (all)	2	5
Eczema	Additional description: Eczema	
subjects affected / exposed	1 / 127 (0.79%)	1 / 127 (0.79%)
occurrences (all)	6	1
Erythema	Additional description: Erythema	
subjects affected / exposed	6 / 127 (4.72%)	1 / 127 (0.79%)
occurrences (all)	7	1
Erythrosis	Additional description: Erythrosis	
subjects affected / exposed	1 / 127 (0.79%)	1 / 127 (0.79%)
occurrences (all)	1	1
Haemorrhage subcutaneous	Additional description: Haemorrhage subcutaneous	
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)
occurrences (all)	1	0
Henoch-Schonlein purpura	Additional description: Henoch-Schonlein purpura	
subjects affected / exposed	0 / 127 (0.00%)	1 / 127 (0.79%)
occurrences (all)	0	1
Hyperhidrosis	Additional description: Hyperhidrosis	
subjects affected / exposed	4 / 127 (3.15%)	1 / 127 (0.79%)
occurrences (all)	4	1

Hyperkeratosis	Additional description: Hyperkeratosis	
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)
occurrences (all)	1	0
Night sweats	Additional description: Night sweats	
subjects affected / exposed	2 / 127 (1.57%)	4 / 127 (3.15%)
occurrences (all)	2	4
Photosensitivity reaction	Additional description: Photosensitivity reaction	
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)
occurrences (all)	1	0
Pruritus	Additional description: Pruritus	
subjects affected / exposed	10 / 127 (7.87%)	9 / 127 (7.09%)
occurrences (all)	75	11
Pruritus generalised	Additional description: Pruritus generalised	
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)
occurrences (all)	2	0
Psoriasis	Additional description: Psoriasis	
subjects affected / exposed	2 / 127 (1.57%)	1 / 127 (0.79%)
occurrences (all)	2	1
Rash	Additional description: Rash	
subjects affected / exposed	3 / 127 (2.36%)	5 / 127 (3.94%)
occurrences (all)	3	7
Rash erythematous	Additional description: Rash erythematous	
subjects affected / exposed	1 / 127 (0.79%)	1 / 127 (0.79%)
occurrences (all)	1	1
Rash papular	Additional description: Rash papular	
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)
occurrences (all)	1	0
Rosacea	Additional description: Rosacea	
subjects affected / exposed	0 / 127 (0.00%)	2 / 127 (1.57%)
occurrences (all)	0	2
Skin disorder	Additional description: Skin disorder	
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)
occurrences (all)	1	0
Skin exfoliation	Additional description: Skin exfoliation	
subjects affected / exposed	1 / 127 (0.79%)	0 / 127 (0.00%)
occurrences (all)	1	0

Skin fissures subjects affected / exposed occurrences (all)	Additional description: Skin fissures	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Skin hyperpigmentation subjects affected / exposed occurrences (all)	Additional description: Skin hyperpigmentation	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Skin swelling subjects affected / exposed occurrences (all)	Additional description: Skin swelling	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Skin ulcer subjects affected / exposed occurrences (all)	Additional description: Skin ulcer	
	0 / 127 (0.00%) 0	7 / 127 (5.51%) 9
Urticaria subjects affected / exposed occurrences (all)	Additional description: Urticaria	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Xeroderma subjects affected / exposed occurrences (all)	Additional description: Xeroderma	
	2 / 127 (1.57%) 4	0 / 127 (0.00%) 0
Renal and urinary disorders		
Calculus urinary subjects affected / exposed occurrences (all)	Additional description: Calculus urinary	
	3 / 127 (2.36%) 7	1 / 127 (0.79%) 1
Chronic kidney disease subjects affected / exposed occurrences (all)	Additional description: Chronic kidney disease	
	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1
Diabetic nephropathy subjects affected / exposed occurrences (all)	Additional description: Diabetic nephropathy	
	1 / 127 (0.79%) 2	0 / 127 (0.00%) 0
Dysuria subjects affected / exposed occurrences (all)	Additional description: Dysuria	
	2 / 127 (1.57%) 2	3 / 127 (2.36%) 3
Haematuria subjects affected / exposed occurrences (all)	Additional description: Haematuria	
	1 / 127 (0.79%) 2	3 / 127 (2.36%) 3
Leukocyturia	Additional description: Leukocyturia	

subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	3 / 127 (2.36%) 3	
Micturition urgency	Additional description: Micturition urgency		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	0 / 127 (0.00%) 0	
Nephrolithiasis	Additional description: Nephrolithiasis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	2 / 127 (1.57%) 2	
Nephropathy	Additional description: Nephropathy		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Nephropathy toxic	Additional description: Nephropathy toxic		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Nephroptosis	Additional description: Nephroptosis		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 2	
Nocturia	Additional description: Nocturia		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Proteinuria	Additional description: Proteinuria		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 3	
Pyelocaliectasis	Additional description: Pyelocaliectasis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Renal cyst	Additional description: Renal cyst		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	7 / 127 (5.51%) 7	
Renal colic	Additional description: Renal colic		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	2 / 127 (1.57%) 2	
Tubulointerstitial nephritis	Additional description: Tubulointerstitial nephritis		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Urinary incontinence	Additional description: Urinary incontinence		

subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Urinary retention	Additional description: Urinary retention		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Urinary tract disorder	Additional description: Urinary tract disorder		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Endocrine disorders			
Autoimmune thyroiditis	Additional description: Autoimmune thyroiditis		
subjects affected / exposed occurrences (all)	4 / 127 (3.15%) 4	1 / 127 (0.79%) 1	
Goitre	Additional description: Goitre		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Hyperthyroidism	Additional description: Hyperthyroidism		
subjects affected / exposed occurrences (all)	4 / 127 (3.15%) 4	0 / 127 (0.00%) 0	
Hypothyroidism	Additional description: Hypothyroidism		
subjects affected / exposed occurrences (all)	7 / 127 (5.51%) 7	2 / 127 (1.57%) 2	
Thyroiditis	Additional description: Thyroiditis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Musculoskeletal and connective tissue disorders			
Arthralgia	Additional description: Arthralgia		
subjects affected / exposed occurrences (all)	18 / 127 (14.17%) 39	6 / 127 (4.72%) 10	
Arthritis	Additional description: Arthritis		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	
Arthritis reactive	Additional description: Arthritis reactive		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 2	0 / 127 (0.00%) 0	
Back pain	Additional description: Back pain		

subjects affected / exposed occurrences (all)	13 / 127 (10.24%) 18	7 / 127 (5.51%) 10	
Bone pain	Additional description: Bone pain		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 3	3 / 127 (2.36%) 3	
Bursitis	Additional description: Bursitis		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	
Diffuse idiopathic skeletal hyperostosis	Additional description: Diffuse idiopathic skeletal hyperostosis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Gouty arthritis	Additional description: Gouty arthritis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Groin pain	Additional description: Groin pain		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Haemarthrosis	Additional description: Haemarthrosis		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Intervertebral disc protrusion	Additional description: Intervertebral disc protrusion		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Joint swelling	Additional description: Joint swelling		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 3	
Muscle spasms	Additional description: Muscle spasms		
subjects affected / exposed occurrences (all)	4 / 127 (3.15%) 4	3 / 127 (2.36%) 3	
Muscular weakness	Additional description: Muscular weakness		
subjects affected / exposed occurrences (all)	4 / 127 (3.15%) 5	0 / 127 (0.00%) 0	
Musculoskeletal chest pain	Additional description: Musculoskeletal chest pain		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 8	1 / 127 (0.79%) 1	

Musculoskeletal pain subjects affected / exposed occurrences (all)	Additional description: Musculoskeletal pain	
	5 / 127 (3.94%) 14	0 / 127 (0.00%) 0
Musculoskeletal stiffness subjects affected / exposed occurrences (all)	Additional description: Musculoskeletal stiffness	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	Additional description: Myalgia	
	12 / 127 (9.45%) 20	6 / 127 (4.72%) 11
Neck pain subjects affected / exposed occurrences (all)	Additional description: Neck pain	
	2 / 127 (1.57%) 2	1 / 127 (0.79%) 1
Osteoarthritis subjects affected / exposed occurrences (all)	Additional description: Osteoarthritis	
	7 / 127 (5.51%) 8	2 / 127 (1.57%) 3
Osteochondrosis subjects affected / exposed occurrences (all)	Additional description: Osteochondrosis	
	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1
Osteopenia subjects affected / exposed occurrences (all)	Additional description: Osteopenia	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Osteoporosis subjects affected / exposed occurrences (all)	Additional description: Osteoporosis	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	Additional description: Pain in extremity	
	10 / 127 (7.87%) 16	6 / 127 (4.72%) 6
Rotator cuff syndrome subjects affected / exposed occurrences (all)	Additional description: Rotator cuff syndrome	
	2 / 127 (1.57%) 2	0 / 127 (0.00%) 0
Scoliosis subjects affected / exposed occurrences (all)	Additional description: Scoliosis	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Sjogren's syndrome subjects affected / exposed occurrences (all)	Additional description: Sjogren's syndrome	
	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1

Spinal osteoarthritis subjects affected / exposed occurrences (all)	Additional description: Spinal osteoarthritis	
	1 / 127 (0.79%) 2	1 / 127 (0.79%) 1
Spinal retrolisthesis subjects affected / exposed occurrences (all)	Additional description: Spinal retrolisthesis	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Spinal pain subjects affected / exposed occurrences (all)	Additional description: Spinal pain	
	4 / 127 (3.15%) 4	5 / 127 (3.94%) 5
Spondylolisthesis subjects affected / exposed occurrences (all)	Additional description: Spondylolisthesis	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Temporomandibular joint syndrome subjects affected / exposed occurrences (all)	Additional description: Temporomandibular joint syndrome	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Tendonitis subjects affected / exposed occurrences (all)	Additional description: Tendonitis	
	2 / 127 (1.57%) 2	1 / 127 (0.79%) 1
Infections and infestations	Additional description: Alveolar osteitis	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Alveolar osteitis subjects affected / exposed occurrences (all)	Additional description: Acute sinusitis	
	2 / 127 (1.57%) 3	2 / 127 (1.57%) 2
Acute sinusitis subjects affected / exposed occurrences (all)	Additional description: Borrelia infection	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Borrelia infection subjects affected / exposed occurrences (all)	Additional description: Bronchitis	
	6 / 127 (4.72%) 10	12 / 127 (9.45%) 13
Bronchitis subjects affected / exposed occurrences (all)	Additional description: COVID-19	
	3 / 127 (2.36%) 3	3 / 127 (2.36%) 3
COVID-19 subjects affected / exposed occurrences (all)	Additional description: COVID-19 pneumonia	
COVID-19 pneumonia		

subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Conjunctivitis	Additional description: Conjunctivitis		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 3	1 / 127 (0.79%) 2	
Chronic sinusitis	Additional description: Chronic sinusitis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Cystitis	Additional description: Cystitis		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 7	3 / 127 (2.36%) 6	
Ear infection	Additional description: Ear infection		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	0 / 127 (0.00%) 0	
Erysipelas	Additional description: Erysipelas		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	0 / 127 (0.00%) 0	
Folliculitis	Additional description: Folliculitis		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 2	
Fungal infection	Additional description: Fungal infection		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Fungal skin infection	Additional description: Fungal skin infection		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 3	0 / 127 (0.00%) 0	
Furuncle	Additional description: Furuncle		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Gastroenteritis	Additional description: Gastroenteritis		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	
Gastrointestinal viral infection	Additional description: Gastrointestinal viral infection		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Herpes zoster	Additional description: Herpes zoster		

subjects affected / exposed occurrences (all)	5 / 127 (3.94%) 5	2 / 127 (1.57%) 2	
Hordeolum	Additional description: Hordeolum		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Infected dermal cyst	Additional description: Infected dermal cyst		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Infection	Additional description: Infection		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	1 / 127 (0.79%) 1	
Influenza	Additional description: Influenza		
subjects affected / exposed occurrences (all)	6 / 127 (4.72%) 7	15 / 127 (11.81%) 15	
Laryngitis	Additional description: Laryngitis		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 3	0 / 127 (0.00%) 0	
Lower respiratory tract infection	Additional description: Lower respiratory tract infection		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Lyme disease	Additional description: Lyme disease		
subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 3	0 / 127 (0.00%) 0	
Nasopharyngitis	Additional description: Nasopharyngitis		
subjects affected / exposed occurrences (all)	9 / 127 (7.09%) 20	14 / 127 (11.02%) 24	
Oesophageal candidiasis	Additional description: Oesophageal candidiasis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Onychomycosis	Additional description: Onychomycosis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Oral candidiasis	Additional description: Oral candidiasis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Oral fungal infection	Additional description: Oral fungal infection		

subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Oral herpes	Additional description: Oral herpes		
subjects affected / exposed occurrences (all)	5 / 127 (3.94%) 5	3 / 127 (2.36%) 4	
Oral infection	Additional description: Oral infection		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Otitis externa	Additional description: Otitis externa		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Parainfluenzae virus infection	Additional description: Parainfluenzae virus infection		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Paronychia	Additional description: Paronychia		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Periodontitis	Additional description: Periodontitis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Pharyngitis	Additional description: Pharyngitis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	3 / 127 (2.36%) 7	
Pharyngotonsillitis	Additional description: Pharyngotonsillitis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Pneumonia	Additional description: Pneumonia		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	1 / 127 (0.79%) 4	
Pulpitis dental	Additional description: Pulpitis dental		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Pyelonephritis acute	Additional description: Pyelonephritis acute		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Pyelonephritis chronic	Additional description: Pyelonephritis chronic		

subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Respiratory tract infection	Additional description: Respiratory tract infection		
subjects affected / exposed occurrences (all)	4 / 127 (3.15%) 4	4 / 127 (3.15%) 4	
Respiratory tract infection viral	Additional description: Respiratory tract infection viral		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1	
Rhinitis	Additional description: Rhinitis		
subjects affected / exposed occurrences (all)	7 / 127 (5.51%) 9	3 / 127 (2.36%) 4	
Rhinotracheitis	Additional description: Rhinotracheitis		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 2	0 / 127 (0.00%) 0	
Sinusitis	Additional description: Sinusitis		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	4 / 127 (3.15%) 5	
Staphylococcal infection	Additional description: Staphylococcal infection		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Tinea versicolour	Additional description: Tinea versicolour		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Tonsillitis	Additional description: Tonsillitis		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	1 / 127 (0.79%) 1	
Tooth infection	Additional description: Tooth infection		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 2	1 / 127 (0.79%) 1	
Tracheitis	Additional description: Tracheitis		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Urinary tract infection	Additional description: Urinary tract infection		
subjects affected / exposed occurrences (all)	8 / 127 (6.30%) 17	8 / 127 (6.30%) 11	
Upper respiratory tract infection	Additional description: Upper respiratory tract infection		

subjects affected / exposed occurrences (all)	11 / 127 (8.66%) 18	7 / 127 (5.51%) 12	
Viraemia	Additional description: Viraemia		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	2 / 127 (1.57%) 2	
Viral infection	Additional description: Viral infection		
subjects affected / exposed occurrences (all)	6 / 127 (4.72%) 6	0 / 127 (0.00%) 0	
Vulvovaginal mycotic infection	Additional description: Vulvovaginal mycotic infection		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	2 / 127 (1.57%) 2	
Metabolism and nutrition disorders	Additional description: Decreased appetite		
Decreased appetite subjects affected / exposed occurrences (all)	3 / 127 (2.36%) 3	2 / 127 (1.57%) 3	
Dehydration	Additional description: Dehydration		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	
Diabetes mellitus	Additional description: Diabetes mellitus		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	0 / 127 (0.00%) 0	
Diabetic metabolic decompensation	Additional description: Diabetic metabolic decompensation		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Dyslipidaemia	Additional description: Dyslipidaemia		
subjects affected / exposed occurrences (all)	2 / 127 (1.57%) 2	1 / 127 (0.79%) 1	
Folate deficiency	Additional description: Folate deficiency		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Gout	Additional description: Gout		
subjects affected / exposed occurrences (all)	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0	
Hypercalcaemia	Additional description: Hypercalcaemia		
subjects affected / exposed occurrences (all)	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1	

Hyperchloraemia subjects affected / exposed occurrences (all)	Additional description: Hyperchloraemia	
	1 / 127 (0.79%) 1	0 / 127 (0.00%) 0
Hypercholesterolaemia subjects affected / exposed occurrences (all)	Additional description: Hypercholesterolaemia	
	1 / 127 (0.79%) 1	2 / 127 (1.57%) 3
Hyperglycaemia subjects affected / exposed occurrences (all)	Additional description: Hyperglycaemia	
	5 / 127 (3.94%) 6	1 / 127 (0.79%) 1
Hyperkalaemia subjects affected / exposed occurrences (all)	Additional description: Hyperkalaemia	
	1 / 127 (0.79%) 2	3 / 127 (2.36%) 5
Hyperlipidaemia subjects affected / exposed occurrences (all)	Additional description: Hyperlipidaemia	
	1 / 127 (0.79%) 1	2 / 127 (1.57%) 2
Hypernatraemia subjects affected / exposed occurrences (all)	Additional description: Hypernatraemia	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	Additional description: Hypertriglyceridaemia	
	1 / 127 (0.79%) 1	4 / 127 (3.15%) 4
Hyperuricaemia subjects affected / exposed occurrences (all)	Additional description: Hyperuricaemia	
	4 / 127 (3.15%) 6	3 / 127 (2.36%) 4
Hypoalbuminaemia subjects affected / exposed occurrences (all)	Additional description: Hypoalbuminaemia	
	3 / 127 (2.36%) 3	0 / 127 (0.00%) 0
Hypocalcaemia subjects affected / exposed occurrences (all)	Additional description: Hypocalcaemia	
	5 / 127 (3.94%) 10	2 / 127 (1.57%) 6
Hypoglycaemia subjects affected / exposed occurrences (all)	Additional description: Hypoglycaemia	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Hypokalaemia subjects affected / exposed occurrences (all)	Additional description: Hypokalaemia	
	2 / 127 (1.57%) 4	1 / 127 (0.79%) 2

Hypomagnesaemia subjects affected / exposed occurrences (all)	Additional description: Hypomagnesaemia	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Hyponatraemia subjects affected / exposed occurrences (all)	Additional description: Hyponatraemia	
	2 / 127 (1.57%) 2	0 / 127 (0.00%) 0
Hypoproteinaemia subjects affected / exposed occurrences (all)	Additional description: Hypoproteinaemia	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Iron deficiency subjects affected / exposed occurrences (all)	Additional description: Iron deficiency	
	8 / 127 (6.30%) 14	4 / 127 (3.15%) 10
Magnesium deficiency subjects affected / exposed occurrences (all)	Additional description: Magnesium deficiency	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Steroid diabetes subjects affected / exposed occurrences (all)	Additional description: Steroid diabetes	
	0 / 127 (0.00%) 0	1 / 127 (0.79%) 1
Type 2 diabetes mellitus subjects affected / exposed occurrences (all)	Additional description: Type 2 diabetes mellitus	
	1 / 127 (0.79%) 1	1 / 127 (0.79%) 1
Vitamin D deficiency subjects affected / exposed occurrences (all)	Additional description: Vitamin D deficiency	
	3 / 127 (2.36%) 3	1 / 127 (0.79%) 1

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/32014125>

<http://www.ncbi.nlm.nih.gov/pubmed/32814349>

<http://www.ncbi.nlm.nih.gov/pubmed/33134869>